Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 31, 2015 6:10 PM ET

Biotechnology

Company Overview of Akebia Therapeutics, Inc.

Company Overview

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is AKB-6548, an oral therapy which has completed a Phase 2b study for the treatment of anemia related to chronic kidney disease in non-dialysis patients, as well as tested in a Phase 2 study for the treatment of anemia in patients undergoing dialysis. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

245 First Street

Suite 1100

Cambridge, MA 02142

United States

Founded in 2007

41 Employees

Phone:

617-871-2098

Fax:

617-871-2099

Key Executives for Akebia Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 51
Total Annual Compensation: $552.3K
Chief Financial Officer, Senior Vice President and Treasurer
Age: 47
Total Annual Compensation: $415.9K
Chief Medical Officer and Senior Vice President
Age: 62
Total Annual Compensation: $181.5K
Compensation as of Fiscal Year 2014.

Akebia Therapeutics, Inc. Key Developments

Akebia Therapeutics, Inc. Announces Resignation of Jack Nielsen as Class II Director and Member of Compensation Committee and Chairman of the Nominating and Corporate Governance Committee

On June 11, 2015, Jack Nielsen, a Class II Director, notified the Board of Directors of Akebia Therapeutics, Inc. of his intention to resign and submitted his resignation from the Board effective immediately. Prior to his resignation, Mr. Nielsen was a member of the Board's Compensation Committee and the Chairman of the Nominating and Corporate Governance Committee.

Akebia Therapeutics, Inc. Announces Presentation of Phase 2B Data for AKB-6548 in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease

Akebia Therapeutics, Inc. announced that data for AKB-6548, a once-daily, oral therapy for the treatment of anemia related to chronic kidney disease (CKD), were presented on May 29, 2015 at the 2015 European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) 52nd Congress, which is being held from May 28 – 31, 2015 in London. The placebo-controlled, 20-week Phase 2b study enrolled 210 patients with CKD stages 3, 4 and 5 who were randomized 2:1 to receive once-daily AKB-6548 (N=138) or placebo (N=72). Patients were assigned to one of three study groups based on recombinant erythropoiesis stimulating agent (rESA) treatment exposure: rESA treatment naïve, rESA previously treated, or rESA actively treated. The initial 450mg daily dose of AKB-6548 was adjusted in accordance with the patient's hemoglobin response using a dose titration algorithm designed to minimize HGB excursions of greater than 13.0 g/dL. In this Phase 2b trial, treatment with AKB-6548 controlled hemoglobin (HGB) levels in a sustained manner and in the clinically relevant range, producing a coordinated physiologic response to resolve anemia while avoiding excessive fluctuations in HGB levels which have been associated with increased cardiovascular risks. AKB-6548 was generally well tolerated in the Phase 2b trial and overall adverse events were balanced between the treatment and placebo groups (74.6% vs. 73.6%). New data presented on May 29, 2015, showed that the group of patients converted from active rESA therapy to AKB-6548 maintained their mean baseline HGB level of 10.5 g/dL throughout the study. In contrast, patients who were switched from active rESA therapy to placebo experienced a decline in the mean HGB level from 10.4 g/dL to 9.8 g/dL within the first two weeks of randomization. These results support a starting dose of 450 mg once daily for patients converting from rESAs to AKB-6548.

Akebia Therapeutics, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 02:00 PM

Akebia Therapeutics, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 02:00 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: John P. Butler, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
Calretex, LLC United States
Receptor BioLogix, Inc. United States
Floratine BioSciences, Inc. United States
Genetic Vectors, Inc. United States
Exemplar Genetics LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Akebia Therapeutics, Inc., please visit www.akebia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.